In the last 3 years, ArchiMed has acquired 3 companies.
ArchiMed’s most common sectors for investment are healthcare services (42%) and medical products (25%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (59%) and growth capital (17%). In total, ArchiMed has invested in 1 US state and 6 different countries. Its largest (disclosed) acquisition occurred in 2019 when it acquired Bomi Italia for $79M.
In the last 3 years, ArchiMed has exited 1 company. The Firm’s most common exit type is secondary buyout (100%).
Join Mergr to view ArchiMed’s full profile and discover more middle-market private equity firms just like it.
ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €5 to €30 million per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.
Join Mergr to view the latest updates and news from ArchiMed.
We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.
Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.
Try us for 1 week free today!
No obligation. Cancel anytime.